The Nano-Integrated Molecular Imaging for Therapeutic Innovation (NIMITI) project aims to develop a breakthrough imaging platform that combines high-throughput single-molecule imaging (NanoLoom) with cryo-electron microscopy (cryo-EM) to accelerate drug discovery. By enabling real-time analysis of molecular interactions, this technology will improve the identification and optimization of novel antibiotics, particularly targeting multidrug-resistant Mycobacterium tuberculosis (M. tuberculosis).

Next-generation molecular imaging

NanoLoom is an innovative single-molecule imaging technology that allows for real-time visualization of DNA-protein interactions. Unlike traditional bulk biochemical assays, it eliminates averaging effects, capturing rare molecular events with high precision. By integrating NanoLoom with cryo-EM, the project aims to create a powerful workflow that correlates dynamic molecular behavior with high-resolution structural data, significantly advancing antibiotic development.

Transforming drug discovery for antibiotic resistance

NIMITI addresses a major global health challenge—the rise of antibiotic-resistant bacterial infections. By studying the bacterial replisome, the machinery responsible for DNA replication, the project will provide critical insights into how antibiotics interact with their targets. This workflow will not only accelerate the development of new antibiotics but also have broad applications in studying cancer, neurodegenerative diseases, and other DNA-related disorders.

Collaboration for innovation

The project is a partnership between 1NA Technologies and the Meindert Lamers group at LUMC, bringing together cutting-edge nanotechnology, molecular imaging, and cryo-EM. This collaboration strengthens academic-industry ties and supports the Netherlands' leadership in advanced molecular imaging technologies for therapeutic innovation.